Connect with us
Finance Digest is a leading online platform for finance and business news, providing insights on banking, finance, technology, investing,trading, insurance, fintech, and more. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

NEWS

Tonix’s long COVID drug fails to meet mid-stage trial goal

Tonix’s long COVID drug fails to meet mid-stage trial goal

(Reuters) – Tonix Pharmaceuticals Holding Corp said on Tuesday its experimental drug failed to meet the primary goal in a mid-stage study for management of widespread muscle pain and tenderness associated with long COVID-19.

Shares of the company were down 12% in premarket trading.

The 63-patient study was designed to monitor the intensity of pain in patients who had long COVID and administered either the drug, TNX-102 SL, or placebo, but the trial failed to show improvement at week 14 of treatment, the company said.

However, the study showed that the drug helped reduce fatigue and improve sleep quality and cognitive function in the patients, the company said.

Tonix intends to meet officials from the U.S. Food and Drug Administration in early 2024 to seek permission to conduct a late-stage trial that focuses on reducing fatigue in patients with long COVID, an illness with no approved drugs.

 

(Reporting by Leroy Leo in Bengaluru; Editing by Dhanya Ann Thoppil)

 

Continue Reading

Why pay for news and opinions when you can get them for free?

       Subscribe for free now!


By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Posts